GSK: A Global Leader with a Bold Purpose- Getting Ahead of Disease, Together
Sep 15, 2025 ACCA Member Spotlight
A Global Leader with a Bold Purpose
When you think of innovation in healthcare, GSK is often at the forefront. As a global biopharma company, GSK’s purpose is clear: to unite science, technology and talent to get ahead of disease together.
From specialty medicines and vaccines to general medicines, GSK focuses on the science of the immune system and advanced technologies. With investments across four therapeutic areas -respiratory, immunology and inflammation, oncology, and HIV and infectious diseases, GSK is striving to make a difference in health at scale. Their Ahead Together strategy aims to positively impact the health of 2.5 billion people by the end of the decade.
Why the Continuing Care Sector Matters
As Canada’s population ages, healthcare systems face new and urgent challenges. Chronic illness, vulnerability to infections, and the strain on care providers all highlight the importance of innovation in continuing care.
For GSK, the connection is clear. Older adults often carry the heaviest burden of disease, making this sector a natural fit for their mission. By focusing on prevention through vaccines, such as those for shingles and respiratory syncytial virus (RSV), and advancing treatments, GSK is helping people live longer, healthier lives while easing pressure on the healthcare system.
Prevention Today for a Healthier Tomorrow
GSK’s investment in vaccines and specialty medicines isn’t just about treating illness; it’s about changing the course of disease. By preventing serious conditions before they take hold, GSK improves quality of life while contributing to the development of more sustainable healthcare systems.
Their work in the continuing care sector reflects a simple but powerful belief: every stage of life deserves to be lived in good health.
Learn More About GSK
Curious to explore how GSK is shaping the future of healthcare? Visit their website to learn more: